Metastatic Melanoma in the Older Patient

Immunologic Insights and Treatment Outcomes

Upendra P Hegde; Nitya Chakraborty; Bijay Mukherji; Jane M Grant Kels


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(2):185-193. 

In This Article

Prognostic Factors of CM in Patients

Outcome data from a large melanoma patient database consistently indicated that the depth of the invasion of melanoma into the dermis, presence of ulceration, number of mitoses per mm2 and presence of metastasis bear important prognostic implications for patients with CM.[2] Cohen et al. reported older age to be an independent marker of poor prognosis in a large study of patients with CM.[7] Although stage IV disease predicts a poor outcome, patients with metastasis in non-visceral sites (i.e., skin or lymph nodes) and those with lung metastasis fare better when compared with metastasis in other visceral sites. Elevated lactate dehydrogenase serves as a powerful marker of aggressive tumor behavior and potential brain metastasis. Once metastatic, the median survival of patients with CM is approximately 6–8 months with currently available treatments.[8]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.